6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one NAMs for mGluR2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders such as depression and cognitive dysfunction, particularly those targeting the metabotropic glutamate receptor subtype 2 (mGluR2), face limitations in efficacy and specificity, with existing negative allosteric modulators and antagonists showing variable results in clinical trials.
Innovation Solution
Development of 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives that act as negative allosteric modulators (NAMs) of the mGluR2 receptor, designed to bind irreversibly to the receptor, offering a novel approach for treating mood disorders, cognitive impairments, and other central nervous system conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing negative allosteric modulators and antagonists of mGluR2 are used for treating neurological disorders, then some therapeutic effect is achieved, but efficacy and specificity are limited with variable results in clinical trials
Solution Approach 1:
The patent introduces specific substituent patterns at defined positions on the core structure (R1 at position 5, R2 at position 3, R3-R6 on the aromatic ring) to achieve selective binding to mGluR2. This local differentiation of molecular properties at specific sites enhances receptor specificity while maintaining therapeutic efficacy, resolving the contradiction between reliability and adaptability.
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types (halo, alkyl, alkoxy, cyano), substituent positions, and core structure modifications to optimize both efficacy and specificity. By changing molecular parameters in a controlled manner, the invention achieves compounds with improved therapeutic reliability and enhanced receptor specificity simultaneously.
2Adaptability or versatility
If current mGluR2-targeting treatments are used, then some neurological disorders are addressed, but variable results are obtained in clinical trials indicating insufficient reliability
Solution Approach 1:
The patent describes a series of compounds with a versatile core structure that can be adapted to target mGluR2 with consistent efficacy across different neurological conditions. The modular substitution pattern allows a single molecular framework to address multiple disorders (depression, cognitive dysfunction, anxiety) reliably, achieving both broad applicability and consistent results.
Solution Approach 2:
The patent replaces the inconsistent binding mechanisms of existing antagonists and allosteric modulators with a novel chemical mechanism based on specific interactions at defined positions on the core structure. This substitution of the binding mechanism through precise molecular design ensures reliable and consistent therapeutic results across different clinical applications.
Data Source
AI summary
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I)as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.